EPHX4: A Protein Targeted for Cancer and Tissue Growth (G253152)

Target Name: EPHX4

NCBI ID: G253152

EPHX4: A Protein Targeted for Cancer and Tissue Growth

EPHX4 (EPHX4_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the Eph receptor tyrosine kinase family, which is a signaling pathway that is involved in the development and maintenance of tissues and organs, as well as in the regulation of cell growth and differentiation.

One of the key functions of EPHX4 is its role in the development and progression of cancer. EPHX4 has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancer. It is also involved in the regulation of the angiogenesis, which is the process by which new blood vessels are formed to support the growth and expansion of cancer cells.

In addition to its role in cancer development, EPHX4 has also been shown to be involved in the regulation of normal tissue growth and development. It has been shown to play a role in the development and maintenance of tissues and organs, such as the liver and pancreas, and has been shown to promote the growth and development of various cell types.

EPHX4 is also involved in the regulation of the immune system, which is a critical part of the body's defense against infection and disease. It has been shown to play a role in the development and regulation of immune cells, including natural killer cells and T- cells, which are important for fighting off cancer cells and other foreign invaders.

Given its involvement in so many different functions of the body, it is not surprising that EPHX4 has become a drug target for various pharmaceutical companies. Currently, there are several drugs that are being developed to target EPHX4, with the goal of using these drugs to treat a variety of diseases, including cancer, immune system disorders, and diseases of the liver and pancreas.

One of the most promising of these drugs is a monoclonal antibody called Adu-TN-1024. This antibody is designed to selectively bind to EPHX4, and to inhibit its ability to promote the growth and survival of cancer cells. Preclinical studies have shown that Adu -TN-1024 is effective in treating various diseases, including breast, ovarian, and colorectal cancer.

Another drug that is being developed to target EPHX4 is a small molecule inhibitor called EPHX4-268. This drug is designed to inhibit the activity of EPHX4, which would reduce its ability to promote the growth and survival of cancer cells. Preclinical studies have shown that EPHX4-268 is effective in treating various cancers, including breast, ovarian, and colorectal cancer.

In addition to these drugs, there are also several other research studies being conducted to better understand the role of EPHX4 in cancer and other diseases. For example, researchers are studying the effects of EPHX4 on the development and progression of various cancer types, as well as its role in the regulation of angiogenesis and immune system function.

Overall, EPHX4 is a protein that is involved in a wide range of important functions of the body, including the development and progression of cancer, the regulation of tissue growth and development, and the immune system. As a result, it is an attractive target for drug development, and there are currently several drugs being developed to target EPHX4, with the goal of using these drugs to treat a variety of diseases.

Protein Name: Epoxide Hydrolase 4

More Common Targets